.png)
A New Decision Layer for Precision Oncology
Precision oncology relies on molecular profiling, but prediction alone is often insufficient. Coral Analytics adds a functional layer by directly measuring how tumour tissue responds to therapy in a controlled ex vivo environment.
Why Functional Evidence Matters?
Cancer treatment decisions are often made under uncertainty. Tumours with similar profiles can respond very differently to the same therapy.
Coral Analytics addresses this gap by measuring treatment response directly in patient-derived tissue before therapy begins.
Direct Response Measurement
Observe real tumour behaviour under therapy conditions.
Clinically Relevant Timing
Generate results within the treatment decision window.
A New Class of Functional Testing Technology
Coral Analytics combines a proprietary ex vivo testing method with ultra high resolution silicon-based detection technology. Patient-derived tumour tissue is processed into standardised microscale samples and exposed in parallel to multiple therapies under controlled conditions.
Biological response is quantified through sensitive metabolic measurement, enabling direct comparison of therapeutic effectiveness within a clinically relevant timeframe.
High resolution detection
Measure metabolic response at microscale using advanced silicon-based sensing
Parallel therapy testing
Evaluate multiple treatment options simultaneously on the same patient-derived sample
Reproducible workflow
Standardised process designed for consistency, scalability, and clinical integration
One Platform.
Two Applications.
Clinical:
Identify the most effective therapy for each patient before committing to treatment.
- Avoid ineffective therapies
- Reduce toxicity
- Accelerate optimal treatment selection
Pharma:
Understand drug response earlier and more directly.
- Functional validation of targets
- Patient stratification
- Reduced trial risk
Partnering to Advance Precision Oncology
Coral Analytics is currently advancing platform development and validation. We welcome collaboration, early partnerships, and discussions with investors.